Fig. 1

Peroxiredoxin 1 was an early phase predictor for the clinical outcomes of cardiogenic shock patients who received ECMO resuscitation. Plasma Peroxiredoxin 1 (Prdx1) (a) and carbonic anhydrase IX (CA IX) (b) levels in the cardiogenic shock patients at the indicated time points after receiving ECMO support according to their 7-day survival status [survivors (n = 32) vs. non-survivors (n = 14)]. Data were expressed as median and interquartile range, while solid circle and open triangle indicated mild and extreme outliers respectively. Statistical differences between groups were analyzed by Mann–Whitney U test